The Impact of Food on Blood Sugar in People With Type 2 Diabetes (REACT2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01237314|
Recruitment Status : Completed
First Posted : November 9, 2010
Last Update Posted : December 2, 2015
This study will record the impact of food on blood glucose levels using continuous glucose monitoring (CGM).
The investigators think the impact will improve as medication doses are adjusted. The investigators also think that the impact will differ depending on the type of medication taken.
|Condition or disease|
|Type 2 Diabetes|
|Study Type :||Observational|
|Actual Enrollment :||46 participants|
|Observational Model:||Case Control|
|Official Title:||Evaluation of the Glycemic Impact of Food in Patients With Type 2 Diabetes Taking Glargine and/or Exenatide|
|Study Start Date :||November 2010|
|Actual Primary Completion Date :||May 2013|
|Actual Study Completion Date :||May 2013|
After baseline titration of metformin, this group will take glargine along with metformin.
After baseline titration of metformin, this group will take exenatide along with metformin.
Glargine and Exenatide Group
After baseline titration of metformin, this group will take glargine and exenatide along with metformin.
- 4-hour glycemic response at 3 time points [ Time Frame: 4 hours ]The four-hour glycemic response includes: four-hour post-meal area under the median interstitial glucose curve, post-meal interstitial glucose peak, time to peak, time to return to pre-prandial level (to within 10% of baseline with a maximum of the 4-hour post-meal fast), difference between peak and baseline, average rate of change in interstitial glucose across the 4 hour post-meal period, and percent of the 4-hour post-meal glucose readings >180 mg/dL.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01237314
|United States, Minnesota|
|International Diabetes Center|
|Minneapolis, Minnesota, United States, 55416|
|Principal Investigator:||Maggie Powers, PhD||International Diabetes Center at Park Nicollet|
|Principal Investigator:||Alice Shapiro, PhD||International Diabetes Center at Park Nicollet|